Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

British Journal of Psychiatry

Volumn 174, Issue MAR., 1999, Pages 238-242

  Poyurovsky, M ^a   Shardorodsky, M ^a   Fuchs, C ^c   Schneidman, M ^a   Weizman, A ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

^c Beilinson Campus ^*

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYPROHEPTADINE; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; GRANISETRON; HALOPERIDOL; LEVODOPA; MIANSERIN; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; PERPHENAZINE; RITANSERIN; SEROTONIN 2 ANTAGONIST; TRIHEXYPHENIDYL;

AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION;

EID: 0033013648     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.174.3.238     Document Type: Article

References (22)

1. Adler, L. A., Peselow, E., Rosenthal, M., et al (1993) A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia, and interim analysis. Psychopharmacology Bulletin, 29, 283-286.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
3. Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Archives of General Psychiatry, 49, 538-544.
5. Fleischhacker, W. W., Rath, S. D. & Kane, J. M. (1990) The pharmacological treatment of neuroleptic-induced akathisia. Journal of Clinical Psychopharmacology, 10, 12-21.
6. Guy, W. (1976) ECDE Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute of Mental Health.
7. Halstead, S. M., Barnes, T. R. E. & Speller, J. C. (1994) Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. British Journal of Psychiatry, 164, 177-183.
8. Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
9. Ikeguchi, K. & Kuroda, A. (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. European Archives of Psychiatry and Clinical Neuroscience, 244, 320-324.
10. Kapur, S. & Remington, G. (1996) Serotonin dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
11. _ & Zipursky, R. B. (1998) Do loxapine plus cyproheptadine make an atypical antipsychotic? PGT analysis of their dopamine D2 and serotonin 2 receptor occupancy. Archives of General Psychiatry, 55, 666-668.
12. Miller, G. H., Fleischhacker, W. W., Ehrman, H., et al (1990) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacology Bulletin, 26, 373-376.
13. _ , Mohr, F., Umbricht, D., et al (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Journal of Clinical Psychiatry, 59, 69-75.
14. Newcomer, J. W., Miller, L. S., Faustman, W. O., et al (1994) Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. British Journal of Psychiatry, 164, 834-838.
15. Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
16. Poyurovsky, M. & Weizman, A. (1997a) SSRIs and akathisia (letter). Journal of Clinical Psychopharmacology, 12, 489.
17. _ & _ (1997b) Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. International Clinical Psychopharmacology, 12, 263-268.
18. _ , Fuchs, C. & Weizman, A. (1998) Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. Journal of Clinical Psychopharmacology, 18, 253-254.
19. Richelson, E. (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. Journal of Clinical Psychiatry, 57 (suppl. 11), 4-10.
20. Salzman, S. K., Kelly, G., Chavin, J., et al (1994) Characterization of mianserin neuroprotection in experimental spinal trauma: dose/route response and late treatment. Journal of Pharmacology and Experimental Therapeutics, 269, 322-328.
21. Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (suppl.), 11-19.
22. Weiss, D., Aizenberg, D., Hermesh, H., et al (1995) Cyproheptadine treatment in neuroleptic-induced akathisia. British Journal of Psychiatry, 167, 483-486.